Core Viewpoint - Interpace Biosciences reported strong financial results for Q1 2025, highlighting record revenues in thyroid testing and a positive outlook for the full year despite the loss of PancraGEN revenue after May 2, 2025 [2][3]. Financial Performance - Q1 2025 net revenue was $11.5 million, a 13% increase from $10.2 million in Q1 2024 [6][7]. - Income from continuing operations was $1.8 million, up from $0.8 million in the prior year quarter, reflecting a $0.9 million improvement [2][7]. - Gross profit margin improved to 64% compared to 62% in the prior year quarter [7]. - Adjusted EBITDA for Q1 2025 was $2.1 million, compared to $1.2 million in Q1 2024 [7][21]. Revenue Growth - Cash collections reached $11.3 million, a 10% increase year-over-year, achieving record levels [6][7]. - Thyroid test revenue was $8.0 million, representing a 19% increase year-over-year, with test volume up 16% [6][7]. Future Guidance - The company initiated full-year 2025 revenue guidance of approximately $38 million, despite anticipated challenges from the loss of PancraGEN revenue [2][3]. Company Overview - Interpace Biosciences is focused on personalized medicine, providing molecular diagnostic tests and bioinformatics services to evaluate cancer risk [5].

Core Viewpoint - Interpace Diagnostics will cease offering the PancraGEN test due to the end of Medicare reimbursement, but the company expects to remain profitable through its thyroid-focused testing services [1][3]. Group 1: Company Overview - Interpace Diagnostics is a subsidiary of Interpace Biosciences, focusing on personalized medicine and molecular diagnostic tests [4]. - The company has three commercialized molecular tests: ThyGeNEXT, ThyraMIRv2, and RespriDX, along with BarreGEN currently in clinical evaluation [5]. Group 2: Impact of Reimbursement Changes - The Genetic Testing for Oncology Local Coverage Determination (LCD) by Novitas Solutions will end reimbursement for the PancraGEN test, effective May 2, 2025 [1][2]. - PancraGEN has been utilized for over a decade to assess the risk of pancreatic cyst progression to cancer, primarily for Medicare patients [2][3]. - The loss of reimbursement will require Interpace to restructure its operations, although the company believes it can sustain profitability without PancraGEN [3]. Group 3: Future Outlook - The company anticipates that its testing franchise for indeterminate thyroid nodules, specifically ThyGeNEXT and ThyraMIRv2, will support continued profitability in 2025 and beyond [3].